Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ECHA InfoCard | 100.244.879 |
Chemical and physical data | |
Formula | C37H42N4O13 |
Molar mass | 750.758 g·mol−1 |
3D model ( JSmol) | |
| |
|
Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate in development by CytRx. Specifically, it is the (6- maleimido caproyl) hydrazone of doxorubicin. Essentially, this chemical name describes doxorubicin attached to an acid-sensitive linker (N-ε-maleimidocaproic acid hydrazide, or EMCH).
The proposed mechanism of action is as follows:
Five phase I trials for safety characterization have been completed. Several phase II and III trials are underway.
As of January 2017, there are 6 phase II clinical trials in progress:
A phase III trial for patients with relapsed soft tissue sarcoma comparing aldoxorubicin with several other chemotherapeutics is expected to complete in 2018. [7] In November 2016, CytRx announced that preliminary results had been positive. [8]
This article includes a list of general
references, but it lacks sufficient corresponding
inline citations. (February 2018) |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ECHA InfoCard | 100.244.879 |
Chemical and physical data | |
Formula | C37H42N4O13 |
Molar mass | 750.758 g·mol−1 |
3D model ( JSmol) | |
| |
|
Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate in development by CytRx. Specifically, it is the (6- maleimido caproyl) hydrazone of doxorubicin. Essentially, this chemical name describes doxorubicin attached to an acid-sensitive linker (N-ε-maleimidocaproic acid hydrazide, or EMCH).
The proposed mechanism of action is as follows:
Five phase I trials for safety characterization have been completed. Several phase II and III trials are underway.
As of January 2017, there are 6 phase II clinical trials in progress:
A phase III trial for patients with relapsed soft tissue sarcoma comparing aldoxorubicin with several other chemotherapeutics is expected to complete in 2018. [7] In November 2016, CytRx announced that preliminary results had been positive. [8]
This article includes a list of general
references, but it lacks sufficient corresponding
inline citations. (February 2018) |